Compare NTLA & GEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTLA | GEL |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Oil Refining/Marketing |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2016 | 1996 |
| Metric | NTLA | GEL |
|---|---|---|
| Price | $13.63 | $15.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 2 |
| Target Price | ★ $20.02 | $19.50 |
| AVG Volume (30 Days) | ★ 5.6M | 237.9K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 4.19% |
| EPS Growth | ★ 27.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $67,671,000.00 | ★ $2,912,770,000.00 |
| Revenue This Year | N/A | $12.12 |
| Revenue Next Year | $62.75 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 16.92 | ★ 43.60 |
| 52 Week Low | $7.95 | $14.55 |
| 52 Week High | $28.24 | $18.64 |
| Indicator | NTLA | GEL |
|---|---|---|
| Relative Strength Index (RSI) | 51.20 | 45.73 |
| Support Level | $11.55 | $14.92 |
| Resistance Level | $14.02 | $16.44 |
| Average True Range (ATR) | 0.94 | 0.45 |
| MACD | 0.11 | 0.05 |
| Stochastic Oscillator | 50.27 | 49.69 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Genesis Energy LP focuses on the midstream segment of the crude oil and natural gas industry. It offers various services to crude oil and natural gas producers, and industrial and commercial enterprises. The company's reportable segments are: Offshore pipeline transportation, Marine transportation, and Onshore transportation and services. Maximum revenue is generated from the Offshore pipeline transportation segment, which includes the transportation and processing of crude oil and natural gas in the Gulf of America. The Marine transportation segment provides waterborne transportation of petroleum products and crude oil throughout North America; and the Onshore transportation and services segment deals with crude oil logistics, sour gas processing, and sells sulfur byproducts.